このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Guizhou Sanli PharmaceuticalLtd 将来の成長

Future 基準チェック /46

Guizhou Sanli PharmaceuticalLtd利益と収益がそれぞれ年間21.1%と24.2%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に19.2% 20.9%なると予測されています。

主要情報

21.2%

収益成長率

21.0%

EPS成長率

Pharmaceuticals 収益成長	17.9%
収益成長率	24.4%
将来の株主資本利益率	19.3%
アナリストカバレッジ	Low
最終更新日	20 Jun 2024

今後の成長に関する最新情報

更新なし

Recent updates

Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Intrinsic Value Is Potentially 73% Above Its Share Price

Apr 23

Guizhou Sanli PharmaceuticalLtd (SHSE:603439) Seems To Use Debt Rather Sparingly

Mar 25

Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Mar 06

業績と収益の成長予測

SHSE:603439 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	3,476	523	N/A	502	2
12/31/2025	2,959	437	N/A	614	3
12/31/2024	2,388	339	N/A	25	2
3/31/2024	1,708	294	205	284	N/A
12/31/2023	1,635	293	168	277	N/A
9/30/2023	1,461	256	215	334	N/A
6/30/2023	1,402	238	200	309	N/A
3/31/2023	1,392	232	81	236	N/A
12/31/2022	1,201	201	173	293	N/A
9/30/2022	1,035	144	42	147	N/A
6/30/2022	992	147	54	148	N/A
3/31/2022	968	153	165	182	N/A
12/31/2021	939	152	129	155	N/A
9/30/2021	881	157	125	174	N/A
6/30/2021	725	117	34	103	N/A
3/31/2021	612	92	36	101	N/A
12/31/2020	630	94	12	63	N/A
9/30/2020	676	88	51	78	N/A
6/30/2020	818	124	121	125	N/A
3/31/2020	888	137	85	92	N/A
12/31/2019	884	133	108	116	N/A
6/30/2019	771	108	91	97	N/A
3/31/2019	754	104	111	112	N/A
12/31/2018	722	110	74	75	N/A
6/30/2018	700	120	65	67	N/A
3/31/2018	665	106	44	46	N/A
12/31/2017	638	88	N/A	57	N/A
9/30/2017	597	77	N/A	43	N/A
6/30/2017	556	66	N/A	28	N/A
3/31/2017	501	68	N/A	19	N/A
12/31/2016	515	75	N/A	35	N/A
9/30/2016	464	69	N/A	30	N/A
6/30/2016	414	63	N/A	26	N/A
3/31/2016	386	58	N/A	29	N/A
12/31/2015	359	53	N/A	33	N/A
9/30/2015	325	46	N/A	28	N/A
6/30/2015	291	40	N/A	23	N/A
3/31/2015	279	34	N/A	12	N/A
12/31/2014	267	29	N/A	1	N/A
12/31/2013	159	19	N/A	30	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 603439の予測収益成長率 (年間21.1% ) は貯蓄率 ( 2.9% ) を上回っています。

収益対市場: 603439の収益 ( 21.1% ) CN市場 ( 22.7% ) よりも低い成長が予測されています。

高成長収益: 603439の収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: 603439の収益 ( 24.2% ) CN市場 ( 13.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: 603439の収益 ( 24.2% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 603439の自己資本利益率は、3年後には低くなると予測されています ( 19.2 %)。

Guizhou Sanli PharmaceuticalLtd 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Recent updates

Guizhou Sanli Pharmaceutical Co.,Ltd to Report First Half, 2024 Results on Aug 29, 2024

Guizhou Sanli Pharmaceutical Co.,Ltd, Annual General Meeting, May 17, 2024

First quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.13 in 1Q 2023)

Now 20% overvalued

Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Intrinsic Value Is Potentially 73% Above Its Share Price

Guizhou Sanli Pharmaceutical Co.,Ltd to Report Q1, 2024 Results on Apr 27, 2024

Guizhou Sanli PharmaceuticalLtd (SHSE:603439) Seems To Use Debt Rather Sparingly

Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Investor sentiment deteriorates as stock falls 18%

Now 21% undervalued

Guizhou Sanli Pharmaceutical Co.,Ltd to Report Fiscal Year 2023 Results on Apr 27, 2024

Now 22% undervalued

Now 21% undervalued

Now 20% undervalued

Guizhou Sanli Pharmaceutical Co.,Ltd (SHSE:603439) announces an Equity Buyback for CNY 40 million worth of its shares.

Third quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.089 in 3Q 2022)

Guizhou Sanli Pharma Plans Acquisition for CNY 499.6 Million

Second quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.10 in 2Q 2022)

Investor sentiment deteriorates as stock falls 16%

Full year 2022 earnings: EPS exceeds analyst expectations

Investor sentiment improves as stock rises 19%

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.089 (vs CN¥0.10 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.11 in 2Q 2021)

GuiZhou SanLi Pharmaceutical Co.,Ltd (SHSE:603439) signed framework agreement to acquire 51% stake in Guizhou Haosite Biotechnology Co., Ltd. from Zhao Guofu.

First quarter 2022 earnings released: EPS: CN¥0.06 (vs CN¥0.06 in 1Q 2021)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

GuiZhou SanLi Pharmaceutical Co., Ltd. (SHSE:603439) agreed to acquire 95% stake in Guiyang Dechang Xiang Pharmaceutical Co., Ltd from Guizhou Jingyi Garden Ecological Planting Co., Ltd. and Guiyang Dechang Xiang Pharmaceutical Co., Ltd.’s Trade Union Committee for CNY 230 million.

Now 21% undervalued

Third quarter 2021 earnings released: EPS CN¥0.10 (vs CN¥0.005 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.053 in 2Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.24 (vs CN¥0.36 in FY 2019)

Investor sentiment deteriorated over the past week

New 90-day low: CN¥15.39

New 90-day low: CN¥18.03

New 90-day low: CN¥20.70

Third quarter earnings released

New 90-day low: CN¥23.10

GuiZhou SanLi Pharmaceutical Co.,LTD. to Report Q3, 2020 Results on Oct 31, 2020

New 90-day low - CN¥26.68

First half earnings released

First half earnings released

GuiZhou SanLi Pharmaceutical Co.,LTD. to Report First Half, 2020 Results on Aug 28, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘